Literature DB >> 11675138

The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology.

K Paulsson1, T Säll, T Fioretos, F Mitelman, B Johansson.   

Abstract

Although trisomy 8 as a sole change is one of the most common chromosomal abnormalities in myeloid malignancies, it is largely unknown if the incidence of this aberration is influenced by other factors of clinical importance. In the present study, the frequencies of isolated +8 in relation to gender, age, previous treatment with chemo- or radiotherapy, and morphologic subtype were ascertained in published, as well as in our own unpublished, cases of acute myeloid leukemia (AML; n=4,246), myelodysplastic syndromes (MDS; n=1,817), and chronic myeloproliferative disorders (MPD; n=530). The frequencies of +8 were higher in MDS and MPD than in AML (7.5% vs. 5.6%; P<0.01) and varied among the morphologic subtypes of AML and MDS (P<0.001 and P<0.05, respectively). Trisomy 8 was more common in women than in men with MPD (11% vs. 5.1%; P<0.05). Furthermore, the frequencies of +8 were higher in de novo AML and MDS than in treatment-related cases (6.0% vs. 2.8%; P<0.01 and 8.6% vs. 1.5%; P<0.001, respectively). The incidence also varied significantly with age in AML (P<0.001), being more common in elderly patients. Although the causes for this frequency heterogeneity remain to be elucidated, possible explanations may include different environmental exposures affecting the origin of +8 in AML, MDS, and MPD and the presence of different underlying cryptic primary aberrations.

Entities:  

Mesh:

Year:  2001        PMID: 11675138     DOI: 10.1016/s0165-4608(01)00486-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

Review 1.  Myelodysplastic syndromes.

Authors:  Olatoyosi Odenike; John Anastasi; Michelle M Le Beau
Journal:  Clin Lab Med       Date:  2011-10-10       Impact factor: 1.935

2.  Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality.

Authors:  Noelle V Frey; Christopher E Leid; Peter C Nowell; Ewa Tomczak; Honore T Strauser; Margaret Kasner; Steven Goldstein; Alison Loren; Edward Stadtmauer; Selina Luger; Elizabeth Hexner; Joanne Hinkle; David L Porter
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

3.  Cytogenetics findings in a histiocytic sarcoma case.

Authors:  J M Alonso-Dominguez; M Calbacho; M Talavera; C Villalon; L Abalo; J V Garcia-Gutierrez; S Lozano; M Tenorio; J Villarrubia; J Lopez-Jimenez; M T Ferro
Journal:  Case Rep Hematol       Date:  2012-06-03

Review 4.  Prognostic Markers of Myelodysplastic Syndromes.

Authors:  Yuliya Andreevna Veryaskina; Sergei Evgenievich Titov; Igor Borisovich Kovynev; Tatiana Ivanovna Pospelova; Igor Fyodorovich Zhimulev
Journal:  Medicina (Kaunas)       Date:  2020-07-27       Impact factor: 2.430

5.  Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies.

Authors:  Liesbeth Lenaerts; Nathalie Brison; Charlotte Maggen; Leen Vancoillie; Huiwen Che; Peter Vandenberghe; Daan Dierickx; Lucienne Michaux; Barbara Dewaele; Patrick Neven; Giuseppe Floris; Thomas Tousseyn; Lore Lannoo; Tatjana Jatsenko; Isabelle Vanden Bempt; Kristel Van Calsteren; Vincent Vandecaveye; Luc Dehaspe; Koenraad Devriendt; Eric Legius; Kris Van Den Bogaert; Joris Robert Vermeesch; Frédéric Amant
Journal:  EClinicalMedicine       Date:  2021-05-13

6.  Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms.

Authors:  Xiaolan Lin; Huifang Huang; Ping Chen
Journal:  Mol Cytogenet       Date:  2020-02-17       Impact factor: 2.009

7.  Karyotyping and prenatal diagnosis of 47,XX,+ 8[67]/46,XX [13] Mosaicism: case report and literature review.

Authors:  Shaohua Sun; Fang Zhan; Jiusheng Jiang; Xuerui Zhang; Lei Yan; Weiyi Cai; Hailiang Liu; Donghua Cao
Journal:  BMC Med Genomics       Date:  2019-12-21       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.